Metastatic Colorectal Cancer Clinical Trials

A listing of 15 Metastatic Colorectal Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Colorectal Cancer

1 - 12 of 15

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 15 active clinical trials seeking participants for Metastatic Colorectal Cancer research studies. The states with the highest number of trials for Metastatic Colorectal Cancer participants are California, Texas, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Clinical Study

Recruiting

We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.

Conditions:

Cough

Chronic Cough

Asthma

Allergic Asthma

Sinusitis

Learn More

Featured Trial

Healthy Volunteer Trials

Recruiting

Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!

Conditions:

Healthy

Learn More

Featured Trial

Healthy Volunteer Clinical Studies

Recruiting

Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.

Conditions:

Healthy

Healthy Volunteers

Learn More

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT01174121

Recruiting

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. Researchers want to know if TIL shrink s tumors in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. In this study, we are selecting a specific subset of white blood cells from the tumor that we think are the most effective in fighting tumors and will use only these cells in making the tumor fighting cells. Objective: The purpose of this study is to see if these specifically selected tumor fighting cells can cause digestive tract, urothelial, breast, or ovarian/endometrial tumors to shrink and to see if this treatment is safe. Eligibility: - Adults age 18-72 with upper or lower gastrointestinal, hepatobiliary, genitourinary, breast, ovarian/endometrial cancer, or glioblastoma refractory to standard chemotherapy. Design: Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed. Surgery: If the patients meet all of the requirements for the study they will undergo surgery to remove a tumor that can be used to grow the TIL product. Leukapheresis: Patients may undergo leukapheresis to obtain additional white blood cells. (Leukapheresis is a common procedure, which removes only the white blood cells from the patient.) Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up to 2 days. Read Less

Gender:

All

Ages:

Between 18 years and 72 years

Trial Updated:

06/19/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors

Learn More ›

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030

Recruiting

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR m... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

06/14/2024

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +172 locations

Banner MD Anderson Cancer Center, Gilbert, Arizona

Local Institution - 0059, Los Angeles, California

Local Institution - 0130, Sacramento, California

Local Institution - 0103, Denver, Colorado

Local Institution, Miami, Florida

Local Institution, Marietta, Georgia

Local Institution - 0119, Arlington Heights, Illinois

Local Institution - 0060, New York, New York

Local Institution - 0105, Portland, Oregon

Local Institution, Philadelphia, Pennsylvania

Local Institution - 0121, Pittsburgh, Pennsylvania

Local Institution - 0106, Dallas, Texas

Local Institution, Fort Worth, Texas

Local Institution - 0104, Roanoke, Virginia

Local Institution - 0073, Ciudad Autonoma Beunos Aires, Buenos Aires

Local Institution - 0074, Viedma, RIO Negro

Local Institution - 0084, Buenos Aires, Not set

Local Institution - 0100, Caba, Not set

Local Institution - 0072, Caba, Not set

Local Institution - 0019, Westmead, New South Wales

Local Institution - 0053, Woolloongabba, Queensland

Local Institution - 0018, Elizabeth Vale, South Australia

Local Institution - 0041, Clayton, Victoria

Local Institution - 0017, Heidelberg, Victoria

Local Institution - 0064, Graz, Not set

Local Institution - 0068, Linz, Not set

Local Institution - 0120, Salzburg, Not set

Local Institution - 0067, Wiener Neustadt, Not set

Local Institution - 0065, Wien, Not set

Local Institution - 0045, Bonheiden, Antwerpen

Local Institution, Brussel, Not set

Local Institution - 0025, Bruxelles, Not set

Local Institution - 0024, Leuven, Not set

Local Institution - 0096, Ipatinga, Minas Gerais

Local Institution - 0200, Natal, RIO Grande DO Norte

Local Institution - 0097, Porto Alegre, Rio Grande Do Sul

Local Institution - 0192, Porto Alegre, RIO Grande DO SUL

Local Institution - 0102, Barretos, Sao Paulo

Local Institution - 0095, Sao Paulo, São Paulo

Local Institution - 0094, São José do Rio Preto, São Paulo

Local Institution - 0199, Rio de Janeiro, Not set

Local Institution - 0193, São Paulo, Not set

Local Institution - 0011, Edmonton, Alberta

Local Institution - 0039, Vancouver, British Columbia

Local Institution, Halifax, Nova Scotia

Local Institution - 0013, Toronto, Ontario

Local Institution - 0016, Montreal, Quebec

Local Institution - 0015, Sherbrooke, Quebec

Local Institution, Quebec, Not set

Local Institution - 0071, Santiago, Metropolitana

Local Institution - 0069, Santiago, Metropolitana

Local Institution - 0070, Independencia, Santiago

Local Institution - 0146, Hefei, Anhui

Local Institution, Fuzhou, Fujian

The First Affiliated hospital of Xiamen University, Xiamen, Fujian

Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, Fujian

Local Institution - 0211, Lanzhou, Gansu

Local Institution - 0158, Foshan, Guangdong

Local Institution - 0194, Guangzhou, Guangdong

Local Institution - 0167, Guangzhou, Guangdong

Local Institution - 0153, Guangzhou, Guangdong

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong

The people's hospital of Guangxi Zhuang autonomous region, Nanning, Guangxi

Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Hunan Cancer Hospital, Changsha, Hunan

The First People's Hospital of Changzhou, Changzhou, Jiangsu

The 1st Affiliate Hospital Of Nanchang University, Nanchang, Jiangxi

The 1st Hospital Of Jilin University, Changchun, Jilin

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

Local Institution - 0188, Xi'an, Shaanxi

Shandong Cancer Hospital, Jinan, Shandong

Local Institution - 0212, Linyi, Shandong

Local Institution - 0154, Qingdao, Shandong

Local Institution - 0165, Yantai, Shandong

Local Institution - 0143, Shanghai, Shanghai

Shanghai East Hospital, Shanghai, Shanghai

Local Institution - 0221, Shanghai, Shanghai

Yunnan Province Cancer Hospital, Kunming, Yunnan

The 2nd Affiliated Hospital Of Z.U.S.M, Hangzhou, Zhejiang

Local Institution - 0206, Ningbo, Zhejiang

Local Institution - 0087, Brno, Not set

Local Institution - 0085, Hradec Kralove, Not set

Local Institution - 0088, Novy Jicin, Not set

Local Institution - 0086, Olomouc, Not set

Local Institution - 0038, Herlev, Not set

Local Institution, Odense, Not set

Local Institution - 0036, Vejle, Not set

Local Institution - 0176, Limoges, Haute-Vienne

Local Institution - 0138, Lille, Nord

Local Institution - 0186, Bayonne, Not set

Local Institution - 0028, Besancon Cedex, Not set

Local Institution - 0029, Lyon Cedex 08, Not set

Local Institution - 0183, Lyon, Not set

Local Institution - 0066, Marseille, Not set

Local Institution - 0030, Montpellier, Not set

Local Institution - 0032, Nantes, Not set

Local Institution - 0027, Paris, Not set

Local Institution - 0061, Pessac Cedex, Not set

Local Institution - 0031, Poitiers, Not set

Local Institution, Rouen, Not set

Local Institution - 0184, Strasbourg, Not set

Local Institution - 0040, Toulouse, Not set

Local Institution - 0042, Dresden, Not set

Local Institution - 0007, Essen, Not set

Local Institution - 0043, Hamburg, Not set

Local Institution - 0117, Hamburg, Not set

Local Institution - 0008, Hannover, Not set

Local Institution - 0009, Heidelberg, Not set

Local Institution - 0044, Marburg, Not set

Local Institution - 0010, Munich, Not set

Local Institution - 0123, Athens, Not set

Local Institution - 0125, Heraklion, Not set

Local Institution - 0124, Holargos, Not set

Local Institution - 0126, Ioannina, Not set

Local Institution - 0091, Dublin 8, Dublin

Local Institution - 0022, Dublin, Not set

Local Institution - 0026, Limerick, Not set

Local Institution - 0055, Catania, Not set

Local Institution - 0003, Genova, Not set

Local Institution - 0001, Milan, Not set

Local Institution - 0004, Napoli, Not set

Local Institution - 0002, Padova, Not set

Local Institution - 0054, Roma, Not set

Local Institution - 0109, Nagoya-shi, Aichi

Local Institution - 0112, Chiba-shi, Chiba

Local Institution - 0107, Kashiwa-shi, Chiba

Local Institution - 0132, Matsuyama, Ehime

Local Institution - 0116, Fukuoka-shi, Fukuoka

Local Institution - 0174, Sapporo-shi, Hokkaido

Local Institution - 0128, Kanazawa-city, Ishikawa

Local Institution - 0111, Kawasaki-shi, Kanagawa

Local Institution - 0175, Yokohama, Kanagawa

Local Institution - 0133, Kumamoto-shi, Kumamoto

Local Institution - 0189, Osaki, Miyagi

Local Institution - 0177, Kurashiki, Okayama

Local Institution - 0115, Suita-shi, Osaka

Local Institution - 0187, Hidaka, Saitama

Local Institution - 0110, Kitaadachigun, Saitama

Local Institution - 0108, Sunto-gun, Shizuoka

Local Institution - 0118, Chuo-ku, Tokyo

Local Institution - 0113, Koto-ku, Tokyo

Local Institution - 0129, Minato-ku, Tokyo

Local Institution - 0114, Osaka, Not set

Local Institution - 0052, Amsterdam, Not set

Local Institution - 0051, Amsterdam, Not set

Local Institution - 0050, Utrecht, Not set

Local Institution - 0033, Bergen, Not set

Local Institution - 0034, Lorenskog, Not set

Local Institution - 0035, Oslo, Not set

Local Institution - 0058, Rio Piedras, Not set

Local Institution - 0076, Cluj-Napoca, Cluj

Local Institution - 0081, Craiova, Dolj

Local Institution - 0168, Brasov, Not set

Local Institution - 0080, Bucharest, Not set

Local Institution, Constanta, Not set

Local Institution - 0205, Iași, Not set

Local Institution - 0089, Suceava, Not set

Local Institution - 0056, Badalona, Barcelona [Barcelona]

Local Institution - 0173, A Coruna, Not set

Local Institution - 0006, Barcelona, Not set

Local Institution, Madrid, Not set

Local Institution - 0005, Madrid, Not set

Local Institution - 0172, Malaga, Not set

Local Institution - 0063, Sevilla, Not set

Local Institution - 0171, Valencia, Not set

Local Institution - 0092, Adana, Not set

Local Institution - 0101, Istanbul, Not set

Local Institution, London, Greater London

Local Institution, Leeds, Yorkshire

Local Institution - 0127, London, Not set

Local Institution - 0049, Oxford, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT06149481

Recruiting

Background: Each year, more than 32,000 people in the United States are diagnosed with colorectal cancer that has returned or progressed after treatment and spread to other organs. This is called metastatic colorectal cancer (mCRC). Most people with mCRC survive only about 2 years. Objective: To test the ability of a combination of up to 4 experimental anti-cancer drugs treat mCRC. The names of these drugs are retifanlimab, TriAdeno vaccine, N-803, and SX-682. They are described below. Eligi... Read More

Gender:

All

Ages:

Between 18 years and 120 years

Trial Updated:

06/04/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Metastatic Colorectal Cancer

Learn More ›

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

NCT05854498

Recruiting

This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/20/2024

Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Conditions: Metastatic Colorectal Cancer

Learn More ›

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

NCT06228326

Recruiting

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector that is designed to stimulate an anti-tumor immune response through the production of cytokines delivered to the airways of people with advanced solid tumor malignancies affecting the lungs via nebulization. This Phase 1, open-label, multicenter, dose escalation and expansion study is designed to evaluate the safety and tolerability of KB707 in adults with with advanced so... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

05/15/2024

Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania +2 locations

Conditions: Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer, Small Cell, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Sarcoma, Metastatic Osteosarcoma

Learn More ›

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526

Recruiting

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/09/2024

Locations: Highlands Oncology Group, Springdale, Arkansas +36 locations

Highlands Oncology Group, Springdale, Arkansas

University of California at Davis, Davis, California

The Oncology Institute of Hope and Innovation, Downey, California

City of Hope Cancer Center, Duarte, California

University of Colorado Hospital, Aurora, Colorado

Nuvance Health, Norwalk, Connecticut

MedStar Georgetown University Hospital, Washington, District of Columbia

Florida Cancer Specialists, Atlantis, Florida

University of Florida Health Cancer Center, Gainesville, Florida

Ocala Oncology Florida Cancer Affiliates, Ocala, Florida

AdventHealth Cancer Institute, Orlando, Florida

Memorial Cancer Institute, Pembroke Pines, Florida

Emory University Winship Cancer Institute, Atlanta, Georgia

Norton Health, Lexington, Kentucky

Greater Baltimore Medical Center, Baltimore, Maryland

The Center for Cancer and Blood Disorders, Bethesda, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

University of Michigan Medical Center, Ann Arbor, Michigan

Atlantic Healthcare System, Morristown, New Jersey

Memorial Sloan Kettering Cancer Center, New York, New York

University of Cincinnati Medical Center, Cincinnati, Ohio

The Ohio State University James Cancer Center, Columbus, Ohio

Zangmeister Cancer Center, Columbus, Ohio

Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center), Gettysburg, Pennsylvania

Prisma Health, Greenville, South Carolina

Tennessee Oncology Chattanooga Memorial Plaza, Chattanooga, Tennessee

Tennessee Oncology - Nashville, Nashville, Tennessee

Houston Methodist Cancer Center, Houston, Texas

Oncology Consultants, Houston, Texas

University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

NEXT/Virginia Cancer Specialists, Fairfax, Virginia

University of Washington / Fred Hutchinson Cancer Center, Seattle, Washington

Newcastle Private Hospital, New Lambton Heights, New South Wales

Tasman Oncology Research, Southport, Queensland

Cancer Research SA, Adelaide, South Australia

Southern Oncology Clinical Research Unit, Bedford Park, South Australia

Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma

Learn More ›

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

NCT06106308

Recruiting

The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/02/2024

Locations: Mayo Clinic - Arizona, Phoenix, Arizona +23 locations

Mayo Clinic - Arizona, Phoenix, Arizona

St. Bernards Medical Center, Jonesboro, Arkansas

Pacific Cancer Medical Center, Anaheim, California

Comprehensive Blood and Cancer Center - Bakersfield, Bakersfield, California

Norris Comprehensive Cancer Center, Los Angeles, California

Torrance Memorial Physician Network - Cancer Care and Infusion Center, Torrance, California

PIH Health, Whittier, California

Memorial Cancer Institute, Hollywood, Florida

Mayo Clinic - Florida, Jacksonville, Florida

Kaiser Permanente, Honolulu, Hawaii

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

The University of Kansas Cancer Center - Westwood, Westwood, Kansas

Cancer Center of Kansas, Wichita, Kansas

Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion, Grand Rapids, Michigan

Mayo Clinic Cancer Center, Rochester, Minnesota

Washington University School of Medicine Center for Advanced Medicine, Saint Louis, Missouri

CCCN, Las Vegas, Nevada

Manhattan Hematology Oncology (MHO) Research Foundation, Inc., New York, New York

Trihealth Kenwood, Cincinnati, Ohio

West Cancer Clinic, Germantown, Tennessee

MD Anderson Cancer Center, Houston, Texas

Utah Cancer Specialists, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Virginia Mason Medical Center, Seattle, Washington

Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation

Learn More ›

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446

Recruiting

The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer that: is metastatic (spread to other parts of the body); has the condition of genetic hypermutability (tendency to mutation) or impaired DNA mismatch repair (MMR) has a certain type of abnormal gene called "BRAF" and; has not received prior treatment. All participants in this study will receive pembrolizumab at the st... Read More

Gender:

All

Ages:

16 years and above

Trial Updated:

04/29/2024

Locations: Mayo Clinic Building - Phoenix, Phoenix, Arizona +108 locations

Mayo Clinic Building - Phoenix, Phoenix, Arizona

Mayo Clinic Hospital, Phoenix, Arizona

Mayo Clinic, Scottsdale, Arizona

Keck Hospital of USC, Los Angeles, California

Keck School of Medicine of USC, Los Angeles, California

LAC USC Medical Center, Los Angeles, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles, California

USC/Norris Comprehensive Cancer Center, Los Angeles, California

Keck Hospital of USC Pasadena, Pasadena, California

Mount Sinai Cancer Center, Miami Beach, Florida

University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida

University of Miami Hospital and Clinics, Sylvester Cancer Center, Plantation, Florida

UChicago Medicine - River East, Chicago, Illinois

University of Chicago Medical Center, Chicago, Illinois

UChicago Medicine at Ingalls - Flossmoor, Flossmoor, Illinois

UChicago Medicine Ingalls Memorial, Harvey, Illinois

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois

The University of Chicago Medicine Center of Advanced Care Orland Park, Orland Park, Illinois

UChicago Medicine at Ingalls - Tinley Park, Tinley Park, Illinois

Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester, Minnesota

Mayo Clinic, Rochester, Minnesota

Columbia University Medical Center, New York, New York

The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee

MD Anderson Cancer Center, Houston, Texas

Chris O'Brien Lifehouse, Camperdown, New South Wales

GenesisCare North Shore, St Leonards, New South Wales

Gallipoli Medical Research Foundation, Brisbane, Queensland

Greenslopes Private Hospital, Greenslopes, Queensland

Austin Health, Heidelberg, Victoria

Peter MacCallum Cancer Centre, Melbourne, Victoria

Royal Melbourne Hospital, Parkville, Victoria

Imelda General Hospital, Bonheiden, Antwerpen

Institut Jules Bordet, Anderlecht, Bruxelles-capitale, Région DE

Cliniques universitaires Saint-Luc, Brussels, Bruxelles-capitale, Région DE

UZ Gent, Gent, Oost-vlaanderen

UZ Leuven, Leuven, Vlaams-brabant

ZNA Middelheim, Antwerpen, Not set

William Osler Health System, Brampton, Ontario

The Ottawa Hospital - General Campus, Ottawa, Ontario

Sunnybrook Health Sciences - Odette Cancer Centre, Toronto, Ontario

CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec

Saskatoon Cancer Center, Saskatoon, Saskatchewan

Fakultni nemocnice Hradec Kralove, Hradec Kralove, Hradec Králové

Fakultni nemocnice Olomouc, Olomouc, Olomoucký KRAJ

Fakultni Thomayerova nemocnice, Prague, Praha 4

Fakultni nemocnice Bulovka, Prague, Praha 8

Rigshospitalet, Copenhagen, Hovedstaden

Herlev and Gentofte Hospital, Copenhagen, Hovedstaden

Aalborg Universitetshospital, Syd, Aalborg, Nordjylland

Vejle Sygehus, Vejle, Syddanmark

Hôpital Européen Georges Pompidou, Paris Cedex 15, Paris

CHU Estaing, Clermont Ferrand, Not set

Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, Not set

Institut Regional du Cancer de Montpellier - ICM Val d'Aurelle, Montpellier Cedex 5, Not set

Institut Régional du Cancer Montpellier, Montpellier, Not set

Hôpital Saint Antoine, Paris, Not set

Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie, Muenchen, Bayern

Institut für Klinisch Onkologische Forschung, Frankfurt, Hessen

Klinikum Oldenburg, Oldenburg, Niedersachsen

Studiengesellschaft BSF Unternehmergesellschaft, Halle (Saale), Sachsen-anhalt

Universitätsklinikum Leipzig, Leipzig, Sachsen

Onkologische Schwerpunktpraxis Kurfuerstendamm, Berlin, Not set

Studiengesellschaft BSF UG, Halle /Saale, Not set

Facharztzentrum Eppendorf, Hamburg, Not set

Policlinico Universitario Monserrato, Monserrato, Cagliari

Azienda Ospedaliera Universitaria dell'Università "Luigi Vanvitelli" Piazza Luigi Miraglia, 2 Napoli, Napoli, Campania

Ospedale di Guastalla, Guastalla, Emilia-romagna

IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia

ASST Grande Ospedale Metropolitano Niguarda, Milan, Milano

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia, Candiolo, Torino

Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno, Livorno, Toscana

Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana

Istituto Oncologico Veneto IRCCS, Padova, Veneto

Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Not set

Istituto Europeo di Oncologia IRCCS, Milano, Not set

Arcispedale Santa Maria Nuova, Reggio Emilia, Not set

Maastricht UMC+, Maastricht, Limburg

Haaglanden MC - locatie Antoniushove, Leidschendam, Zuid-holland

St. Olavs Hospital, Trondheim, Sør-trøndelag

Oslo Universitetssykehus Ullevål, Oslo, Not set

Przychodnia Lekarska KOMED, Konin, Wielkopolskie

Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza, Brzozow, Not set

SPZOZ Wojewodzki Szpital Specjalistyczny nr 4 w Bytomiu, Bytom, Not set

Copernicus Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, Not set

Radomskie Centrum Onkologii im. Bohaterow Radomskiego Czerwca 76, Radom, Not set

Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica, Banska Bystrica, Not set

Onkologicky ustav sv. Alzbety, s.r.o., Bratislava, Not set

Narodny onkologicky ustav, Bratislava, Not set

Vychodoslovensky onkologicky ustav, a.s., Kosice, Not set

CHUS - Hospital Clinico Universitario, Santiago de Compostela, A Coruña [LA Coruña]

Hospital General Universitario de Elche, Elche, Alicante

Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [barcelona]

Hospital Clínic de Barcelona, Barcelona, Catalunya [cataluña]

Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet de Llobregat, Catalunya [cataluña]

Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad DE

Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad DE

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Virgen Del Rocio, Sevilla, Not set

Hospital General Universitario de Valencia, Valencia, Not set

Hospital Universitario Miguel Servet, Zaragoza, Not set

Karolinska Universitetssjukhuset Solna, Solna, Stockholms LÄN [se-01]

Södersjukhuset, Stockholm, Stockholms LÄN [se-01]

Skaraborgs Sjukhus Skövde, Skövde, Not set

Aberdeen Royal Infirmary, Aberdeen, Aberdeen CITY

Guy's & St Thomas's NHS Foundation Trust, London, England

Guy's & St Thomas' NHS Foundation Trust, London, London, CITY OF

Heartlands Hospital, Birmingham, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

NCT04587128

Recruiting

The study will use previously established doses of panitumumab or cetuximab in the metastatic setting for the treatment of unresectable colorectal cancer (CRC). It is designed to investigate an alternative treatment strategy to maximize the benefit to inhibition of epidermal growth factor receptor (EGFR) for a highly selected patient population. It will enroll 71 participants with left-sided, unresectable metastatic CRC. Participants will be on study up to 5 years.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/26/2024

Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Conditions: Metastatic Colorectal Cancer

Learn More ›

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

NCT05985954

Recruiting

To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.

Gender:

All

Ages:

18 years and above

Trial Updated:

03/21/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Metastatic Colorectal Cancer

Learn More ›

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

NCT05743036

Recruiting

The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.

Gender:

All

Ages:

18 years and above

Trial Updated:

03/07/2024

Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +26 locations

USC Norris Comprehensive Cancer Center, Los Angeles, California

Alliance for Multispecialty Research, LLC, Merriam, Kansas

University of Texas MD Anderson Cancer Center, Houston, Texas

The Queen Elizabeth Hospital, Woodville South, South Australia

Peter MacCallum Cancer Centre, Melbourne, Victoria

Hämatologie- Onkologie im Zentrum MVZ GmbH, Augsburg, Bayern

Klinikum der Universität München Großhadern, Muenchen, Bayern

Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie, Muenchen, Bayern

Institut für Klinisch Onkologische Forschung, Frankfurt, Hessen

DRK Kliniken Berlin - Köpenick, Berlin, Not set

Semmelweis University-Department of Internal Medicine and Oncology, Budapest, Not set

Clinexpert Kft. Bugat Pal Korhaz, Gyöngyös, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania

IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia

AOUI Verona, Verona, Veneto

Istituto Europeo di Oncologia, Milano, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

Szpital Uniwersytecki w Krakowie, Kraków, Malopolskie

Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie, Kraków, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie, Warsaw, Mazowieckie

Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego, Opole, Opolskie

Parc de Salut Mar - Hospital del Mar, Barcelona, Cataluna

Hospital Universitario Reina Sofia, Córdoba, Cordoba

Fundación Instituto Valenciano de Oncología, Valencia, Valenciana, Comunitat

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

Immunotherapy for Third Line Metastatic Colorectal Cancer

NCT04444622

Recruiting

This is a Phase IIB multi-site, open label study of a next generation immunotherapy for third-line MSI-S metastatic colorectal cancer using an "off-the-shelf", non-genetically manipulated living immune cell product (AlloStim) derived from the blood of healthy donors.

Gender:

All

Ages:

18 years and above

Trial Updated:

03/04/2024

Locations: Mt. Sinai Comprehensive Cancer Center, Miami Beach, Florida +3 locations

Conditions: Metastatic Colorectal Cancer

Learn More ›

1 - 12 of 15